Skip to content

Search

Showing results for "clinical trials"

Cystic Fibrosis Early Surveillance Program

Researchers are able to track the progress of lung disease through a comprehensive longitudinal set of biological samples, images and data archives.

The Effect of SMS Reminders on Vaccine Hesitancy in New Parents

Tom Snelling BMBS DTMH GDipClinEpid PhD FRACP Head, Infectious Disease Implementation Research 08 6319 1817 tom.snelling@thekids.org.au Head,

Assessing the utility of routine viral surveillance performed in children undergoing autologous stem cell transplantation at a single centre

We assessed the utility of routine viral surveillance for cytomegalovirus, Epstein–Barr virus and human adenovirus in children <16 years, undergoing autologous stem cell transplantation (ASCT) at a single centre over a 10-year period. A total of 85 ASCT were performed in 65 patients.

Bronchopulmonary dysplasia: Rationale for a pathophysiological rather than treatment based approach to diagnosis

This review describes the evolution of bronchopulmonary dysplasia definitions, evaluates the benefits and limitations of each approach

Orthopaedic issues in Rett Syndrome

This chapter reviews the prevalence, characteristics, and clinical management of orthopedic problems in RTT.

Skull base osteomyelitis: Fungal versus Bacterial Infection

An 18-year (1990-2007) retrospective review of patients with Skull-base osteomyelitis (SBO) presenting to Westmead Hospital was performed.

Research Nurse/Officer

The Opportunity This opportunity is within the Neonatal Research Group at The Kids Research Institute Australia. Our core medical and clinical

Clindamycin adjunctive therapy for severe Staphylococcus aureus treatment evaluation (CASSETTE)-an open-labelled pilot randomized controlled trial

Combination antibiotic therapy with an antitoxin agent, such as clindamycin, is included in some guidelines for severe, toxin-mediated Staphylococcus aureus infections. The evidence to support this practice is currently limited to in vitro, animal and observational human case-series data, with no previous randomized controlled trials (RCTs).

RSV prophylaxis use in high-risk infants in Western Australia, 2002-2013: a record linkage cohort study

The monoclonal antibody, palivizumab is licensed for use in high-risk infants to prevent severe illness caused by respiratory syncytial virus (RSV). The level of its use and compliance with current jurisdictional guidelines which were amended in 2010, is unknown.